Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27983491 | 0.84 | BRD4 (0.41) | FFAR1 | |
| SCHEMBL27983484 | 0.84 | BRD4 (0.41) | FFAR1 | |
| SCHEMBL7150533 | 0.81 | LMNA (0.46) | LMNASLC6A3SLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL28192661 | 0.79 | SLC6A2 (0.43) | LMNASLC6A3SLC6A2HTTFFAR1 | |
| SCHEMBL734738 | 0.79 | SLC6A2 (0.43) | LMNASLC6A3SLC6A2HTTFFAR1 | |
| SCHEMBL27983492 | 0.79 | CYP1A2 (0.42) | ALDH1A1 | |
| SCHEMBL27983310 | 0.79 | CYP1A2 (0.42) | ALDH1A1 | |
| SCHEMBL27983483 | 0.79 | CCR3 (0.54) | LMNAALDH1A1HTT | |
| SCHEMBL27983247 | 0.79 | CCR3 (0.54) | LMNAALDH1A1HTT | |
| SCHEMBL8067450 | 0.78 | ALDH1A1 (0.43) | LMNASLC6A3SLC6A2SLC6A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138377-B2 | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use | DOV PHARMACEUTICAL, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080293822-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | ETHISMOS RESEARCH, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080269348-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | ETHISMOS RESEARCH, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080194696-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | ETHISMOS RESEARCH, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194696-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | HTR2C, HTR1B, HTR3C | LMNA 1152/4885SLC6A3 76/4885SLC6A2 150/4885 |
| US-20080293822-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | HTR2C, HTR1B, HTR3C | LMNA 1152/4885SLC6A3 76/4885SLC6A2 150/4885 |
| US-20080269348-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | HTR2C, HTR1B, HTR3C | LMNA 1152/4885SLC6A3 76/4885SLC6A2 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.